Novartis AG beats Q2 2025 expectations, but patent expiries and policy risks loom. Click for my updated look at NVS earnings ...

The HHS secretary and four of his advisers earned at least $3.2 million from their work opposing Big Pharma and promoting ...

More than half of drug launches fall short of forecasts. Engaging payers during trial design and capturing outcomes with real ...

The Motley Fool. DATE Thursday, July 17, 2025 at 9 a.m. ET CALL PARTICIPANTS Chairman and Chief Executive Officer — Robert ...

Closing of the Merger Expected in Early August DUBLIN, July 17, 2025 /PRNewswire/ -- Mallinckrodt plc today announced that the Irish High Court has given the necessary ruling to enable ...

Novartis is launching a $10 billion share buyback to be completed by year-end 2027 as new drug launches accelerate. | ...

Included in the agreement are ranibizumab-nuna 0.05 mL injection (BYOOVIZ), referencing LUCENTIS (ranibizumab), and ...

Closing of the Merger Expected in Early August DUBLIN, July 17, 2025 /PRNewswire/ -- Mallinckrodt plc today announced that the Irish High Court has given ...

While Novartis holds a diversified product portfolio, there is some product concentration with its largest drugs, Entresto (close to 15% of sales) and Cosentyx (close to 10% of sales). Both drugs will ...

In April 2025, the US Food and Drug Administration (FDA) published a roadmap for leveraging new approach methodologies (NAMs), including in silico approaches such as artificial intelligence (AI), to ...

(NYSE:JNJ) announced today that the FDA granted priority review to a new drug application (NDA) for its TAR-200.